Abstract:Extraocular muscles (EOM) are preferentially involved in myasthenia gravis (MG) and acetylcholine receptor (AChR) antibody positive MG patients may occasionally present with isolated ocular symptoms. Although experimental autoimmune myasthenia gravis (EAMG) induced by whole AChR immunization closely mimics clinical and immunopathological aspects of MG, EOM are usually not affected. We have previously developed an EAMG model, which imitates EOM symptoms of MG by immunization of human leukocyte antigen (HLA) transgenic mice with alpha or gamma-subunits of human AChR (H-AChR). To investigate the significance of the epsilon-subunit in ocular MG, we immunized HLA-DR3 and HLA-DQ8 transgenic mice with recombinant H-AChR epsilon-subunit expressed in Escherichia coli. HLA-DR3 transgenic mice showed significantly higher clinical ocular and generalized MG severity scores and lower grip strength values than HLA-DQ8 mice. H-AChR epsilon-subunit-immunized HLA-DR3 transgenic mice had higher serum anti-AChR antibody (IgG, IgG1, IgG2b, IgG2c and IgM) levels, neuromuscular junction IgG and complement deposit percentages than epsilon-subunit-immunized HLA-DQ8 transgenic mice. Control mice immunized with E. coli extract or complete Freund adjuvant (CFA) did not show clinical and immunopathological features of ocular and generalized EAMG. Lymph node cells of epsilon-subunit-immunized HLA-DR3 mice showed significantly higher proliferative responses than those of epsilon-subunit-immunized HLA-DQ8 mice, crude E. coli extract-immunized and CFA-immunized transgenic mice. Our results indicate that the human AChR epsilon-subunit is capable of inducing myasthenic muscle weakness. Diversity of the autoimmune responses displayed by mice expressing different HLA class II molecules suggests that the interplay between HLA class II alleles and AChR subunits might have a profound impact on the clinical course of MG. (C) 2015 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Inhibitory IgG Receptor FcγRIIB Fails to Inhibit Experimental Autoimmune Myasthenia Gravis Pathogenesis

Mice with IFN-gamma Receptor Deficiency Are Less Susceptible to Experimental Autoimmune Myasthenia Gravis.

Both CD4+ and CD8+ T Cells Are Essential to Induce Experimental Autoimmune Myasthenia Gravis.

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis.

Suppression of Experimental Autoimmune Myasthenia Gravis After CD8 Depletion is Associated with Decreased IFN-gamma and IL-4

Cytokines and the Pathogenesis of Myasthenia Gravis

Depletion of CD8+ T Cells Suppresses the Development of Experimental Autoimmune Myasthenia Gravis in Lewis Rats.

Mucosal Tolerance to Experimental Autoimmune Myasthenia Gravis is Associated with Down‐regulation of AChR‐specific IFN‐γ‐expressing Th1‐like Cells and Up‐regulation of TGF‐β Mrna in Mononuclear Cells

Interferon-Gamma-Modified Dendritic Cells Suppress B Cell Function and Ameliorate the Development of Experimental Autoimmune Myasthenia Gravis

Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats.

Genetic Deficiency of Estrogen Receptor Alpha Fails to Influence Experimental Autoimmune Myasthenia Gravis Pathogenesis.

Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR

The susceptibility of Aire−/− mice to experimental myasthenia gravis involves alterations in regulatory T cells

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Ocular Myasthenia Gravis Induced By Human Acetylcholine Receptor Epsilon Subunit Immunization In Hla Dr3 Transgenic Mice

Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis.

Selective Recognition and Elimination of Nicotinic Acetylcholine Receptor-Reactive B Cells by A Recombinant Fusion Protein Achr-Fc in Myasthenia Gravis in Vitro

Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis

Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis

A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats Via Immune Modulation